• Children and young people aged 2 and 18 years fulfilling ILAR diagnostic criteria for JIA (all subgroups that have uveitis) with associated uveitis, or chronic anterior uveitis with no known associated autoimmune disease
• SUN grade 1+ or more for two clinic visits during the preceding 12 weeks therapy despite MTX or MMF, adalimumab and corticosteroid therapy (both systemic and topical). The latest date of SUN grade score must be the date of the screening visit.
• They must have failed adalimumab ((< 30kg 20mg every 2 weeks, > 30 kgs 40mg every 2 weeks) during the 12 weeks prior to screening. The participant must have been on MTX or MMF for at least 12 weeks* and have been on a stable dose for 4 weeks prior to screening visit.
• No Disease modifying immunosuppressive drugs, other than MTX or MMF, in the 4 weeks prior to screening
• Participant and parent/legal guardian willing and able to comply with protocol requirements and provide written informed consent, and assent where appropriate.
• For participants of reproductive potential (males and females), use of a reliable means of contraception** throughout their trial participation. Post pubertal females must have a negative serum pregnancy test within 10 days before the first dose of trial drug.
• Able to be registered and commence trial treatment within 2 weeks of the screening visit.

Patients with the following characteristics will be excluded from the trial:

• Uveitis associated with infection, or history of ocular herpetic disease
• Active inflammatory disease other than JIA and Uveitis
• Currently on a biologic agent or has previously received any other biologic agent (other than adalimumab.)
• Have been on adalimumab within previous 4 weeks
• Currently on more than 1 disease-modifying anti-rheumatic drug (DMARD)
• Chronic uncontrolled JIA and/or uveitis for more than 52 weeks
• More than 6 topical steroid eye drops per eye, per day prior to screening (this dose must have been stable for at least 4 weeks prior to registration)
• For patients on Prednisone or Prednisone equivalent, dose >0.2mg/kg per day or change of dose within 4 weeks prior to registration
• Intra-articular joint injections within 4 weeks prior to registration
• History or current diagnosis of Electrocardiogram (ECG) abnormalities indicating significant risk of safety for patients participating in the study such as:
  • Concomitant clinically significant cardiac arrhythmias, e.g., sustained ventricular tachycardia, and clinically significant second or third degree AV block without a pacemaker
  • History of familial long QT syndrome or known family history of Torsades de Pointes.
• Underlying metabolic, hematologic, renal, hepatic, pulmonary, neurologic, endocrine, cardiac, infectious or gastrointestinal conditions which in the opinion of the Investigator immunocompromises the subject and/or places the subject at unacceptable risk for participation in a study with an immunomodulatory treatment.
• History of active tuberculosis of less than 24 weeks treatment or untreated latent TB or evidence of Latent TB (positive QuantiFERON or PPD at screening) but unwilling or unable to complete a minimum of 4 weeks of latent TB treatment before initiating treatment with secukinumab
• Participant has history of central nervous system (CNS) neoplasm, active CNS infection, demyelinating disease, or any progressive or degenerative neurological disease
• Poorly controlled diabetes or persistently poorly controlled severe hypertension (>95th percentile for height / age) as deemed by the treating physician
• Previous history of malignancy
• Intraocular surgery within the 12 weeks prior to screening (cataract/ glaucoma/ vitrectomy)
• Peri-ocular corticosteroids within 4 weeks prior to screening or intraocular steroid at any time.
• Pregnant or nursing female
• Demonstrations of clinically significant deviations in any of the following laboratory parameters:
  • Screening total white blood cell (WBC) count <3000 /uL, or platelets <100000/ul or neutrophils <1500 /ul or haemoglobin <8.5 g /dL (85 g /L). Any single parameter may not exceed 2 x upper limit of normal (ULN). A single parameter elevated up to and including 2 x ULN should be re-checked once more as soon as possible, and in all cases, at least prior to baseline, to rule out lab error.
  • Serum bilirubin exceeding the value of 1.6 mg/dL (27 umol/L)
• Having been administered a live or attenuated vaccine within 12 weeks prior to screening
• Previous entry into either arm of the trial or first stage of the trial.
• Intra-ocular pressure <6mm Hg , Intra-ocular pressure <25mm Hg or intraocular pressure requiring systemic acetazolamide
• Participated in a trial of a medicinal product within 4 weeks or 5 half-lives, whichever is longer prior to screening visit.
• History of hepatitis B virus
• Any contraindications to secukinumab